TearClear Files IND Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution

TearClear has filed an investigational new drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution 0.005%.     

Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderate to severe ocular surface disease (OSD).¹ Studies have suggested that removal of preservatives may be beneficial for the ocular health of such patients.

TearClear is the first and only company to develop products that keep BAK preserved formulations safely in the bottle and deliver pristine, preservative free drops of trusted medicines to the eye, according to TearClear.

“We are confident that improving the health of the ocular surface matters,” Stuart Raetzman, TearClear’s CEO, said in a company news release. “Responding to that unmet need has propelled us to this important milestone and it is what drives us to expand our efforts for other glaucoma therapies and to important therapies beyond glaucoma that intersect with OSD.”